Literature DB >> 26339890

Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.

Roberta Gualtierotti1, Francesca Ingegnoli2, Rebecca Two3, Pier Luigi Meroni2, Dinesh Khanna4, Giuditta Adorni, Andrea Becciolini, Teresa Ciavarella, Giovanni Marfia, Antonella Murgo, Luciana Scalone, Nicola Ughi, Silvana Zeni.   

Abstract

OBJECTIVES: To test the acceptability, feasibility, reliability and validity of the Italian translated version of the UCLA Scleroderma Clinical Trial Consortium GIT (UCLA-SCTC GIT) 2.0. Gastrointestinal tract (GIT) involvement is frequent in systemic sclerosis (SSc). The UCLA-SCTC GIT 2.0 is a validated instrument for measuring the presence and impact of GIT symptoms in SSc patients.
METHODS: Acceptability and feasibility of the questionnaire were evaluated based on the input from the patients. Internal consistency was evaluated by Cronbach's alpha. External consistency was measured by comparing with the Short Form (SF)-36 and EQ-5D by Spearman's rho, meaningful if ≥0.30.
RESULTS: Sixty-two consecutive SSc patients (mean age 60.6) were recruited, 88.5% were female. The UCLA-SCTC GIT 2.0 was well accepted. Percentage of missing data in UCLA-SCTC GIT total score was 2 %. Internal consistency was acceptable (alpha≥0.70) for all domains. Cronbach's alpha was ≥0.70 for all domains. UCLA-SCTC GIT 2.0 discriminated between patients with or without gastroesophageal reflux disease whether diagnosed clinically or by objective testing (p<0.01 for both). UCLA-SCTC GIT emotional well-being was correlated with the conceptually equivalent SF-36 mental health domains (correlation coefficient>0.35) and with the EQ-5D usual activities domain (0.38), thus reflecting the impact on everyday activities. The distention/bloating domain strongly correlated with the EQ-5D anxiety/depression domain (0.51) and reflux domain with role emotional of SF-36 (0.44).
CONCLUSIONS: This is the first validation study of the Italian version of UCLA-SCTC GIT 2.0. Our data support its feasibility, reliability, and validity in Italian SSc patients.

Entities:  

Mesh:

Year:  2015        PMID: 26339890

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  6 in total

1.  The validity and reliability study of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT) 2.0 questionnaire for the Turkish society.

Authors:  Yaşar Murat Taş; Gözde Derviş Hakim; Pembe Keskinoğlu; Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Fatoş Önen; Nurullah Akkoç; Merih Birlik; Mesut Akarsu
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

2.  Validation of Serbian version of UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in 104 patients with systemic sclerosis.

Authors:  Ana Zekovic; Nemanja Damjanov
Journal:  Rheumatol Int       Date:  2017-03-07       Impact factor: 2.631

3.  Validation of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument 2.0 in English- and Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort.

Authors:  Andrea Hsiu Ling Low; Xiaohui Xin; Weng Giap Law; Gim Gee Teng; Amelia Santosa; Anita Lim; Grace Chan; Swee Cheng Ng; Julian Thumboo
Journal:  Clin Rheumatol       Date:  2017-01-05       Impact factor: 2.980

4.  Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.

Authors:  Barbara Vigone; Monica Caronni; Adriana Severino; Chiara Bellocchi; Anna Rita Baldassarri; Mirella Fraquelli; Gaia Montanelli; Alessandro Santaniello; Lorenzo Beretta
Journal:  Arthritis Res Ther       Date:  2017-06-20       Impact factor: 5.156

5.  Performance of the UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract 2.0 instrument as a clinical decision aid in the routine clinical care of patients with systemic sclerosis.

Authors:  Norina Zampatti; Alexandru Garaiman; Suzana Jordan; Rucsandra Dobrota; Mike Oliver Becker; Britta Maurer; Oliver Distler; Carina Mihai
Journal:  Arthritis Res Ther       Date:  2021-04-22       Impact factor: 5.156

6.  Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports.

Authors:  Nicola Ughi; Chiara Crotti; Francesca Ingegnoli
Journal:  Clin Interv Aging       Date:  2016-03-14       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.